Clinical Trial Update: Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments

View source ↗

Summary

A completed AstraZeneca clinical trial examining how Swiss general practitioners segment GERD patients into three distinct groups.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Snippet

Sponsor: AstraZeneca | Conditions: GERD | Status: COMPLETED